ESR1 and neoplasm: Treatments that target hormone receptors are an attractive option, as studies have shown that ~70% of LGSOCs are positive for estrogen receptor (ER) and ~30% are positive for progesterone receptor (PR), defined as weak (1% to 50% of tumor cell nuclei) or strong (≥50%) (7).